Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — Q1 2024 Earnings Presentation
12 slides from Tty Biopharm's earnings presentation, Jun 26, 2024
Slide 1: TTY Biopharm Operational Results Report
TTY Biopharm 4105 Operational Results Report 2024.06.26
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: Q1/2024 Operational Highlights
Operational Results Report Q1/2024 Operational Highlights Q1/2024 Financial Performance 01 Q1/2024 Operational Highlights 2024 Outlook 2
Slide 4: Strong Revenue with Overseas Market Expansion
Strong Revenue with Overseas Market Expansion Operational Results Report Revenue Overview √ YoY Consolidated Revenue √ Consolidated Operating √ Q1 EPS reached new high Q1/2024 Operational +9% (1.27 billion) Gross Margin 61% for last 5 years 1.13 Highlights Q1/2024 Market Development Highlights Finan
Slide 5: Three Arrows of Operation with Outstanding Results
Three Arrows of Operation with Outstanding Results Operational Results Report Export the Difficulty Generic Drugs • Lipo-AB received US profit sharing Q1/2024 Operational • Lipo-Dox received Pakistan drug license in January Highlights Q1/2024 Self-developed New Drug Financial Performance • Polymyxin
Slide 6: Product Pipeline: Self-develop, License-in, Cooperation
Product Pipeline: Self-develop, License-in, Cooperation Operational Results Report • Alliance with international partners to strengthen the advantage of the product portfolio • Joint-develop specialty of generic drugs with international partners and expand overseas markets Q1/2024 Oncology 2024 2025
Slide 7: Deploy Globally and Expand Overseas Market
Deploy Globally and Expand Overseas Market Operational Results Report • License-in/ collaboration/ sales 130 drugs in 18 countries globally. • The export market will continue to grow and expand steadily, focusing on the development of the US and other major markets. Q1/2024 • Deepen cooperation with
Slide 8: Q1/2024 Financial Performance
Operational Results Report Q1/2024 Operational Highlights Q1/2024 Financial Performance 02 Q1/2024 Financial Performance 2024 Outlook 7
Slide 9: Q1/2024 Financial Performance Income Statement
Q1/2024 Financial Performance Operational Results Report Income Statement Q1/2024 （Unit: NT Thousand, Operational except EPS） 2024 Q1 2023 Q1 YoY % Q1/2024 Financial Performance Highlights Net Sales 1,273,605 1,166,332 9% Operating Cost (500,746) (455,977) 10% • YoY consolidated revenue +9% due to Q
Slide 10: Q1/2024 Steady Revenue Growth
Q1/2024 Steady Revenue Growth Operational Results Report Q1/2024 Revenue Breakdown Q1/ 2024 Revenue Growth Q1/2024 Operational Highlights Product Category % Revenue (NT Mn) 48% $1,320 $ 12 $1,300 $56 Oncology -$2 -$2 Q1/2024 $1,280 $ 1,274 Financial -$24 Intensive Care $1,260 Performance $1,240 $ 68
Slide 11: 2024 Outlook
Operational Results Report Q1/2024 Operational Highlights Q1/2024 Financial Performance 03 2024 Outlook 2024 Outlook 10
Slide 12: Core Strategy and the Three Arrows are Implemented
Core Strategy and the Three Arrows are Implemented Operational Results Report 1 Strengthen Global Deployment Q1/2024 Explore potential products and expand international market through Operational authorization, distribution, strategic cooperation and M&A. Highlights License-in the International New